Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
In vitro anticancer activity of indomethacin sodium (0-150 μM; 24 hours; 3LL-D122 cells) has been reported [2]. Viral protein translation is halted and viral replication is inhibited when indomethacin sodium (0-1000 μM) activates PKR and phosphorylates eLF2α, shielding host cells from viral damage (IC50=2μM) [3].
|
---|---|
ln Vivo |
In male Sprague-Dawley rats, indomethacin sodium (0.01–10 mg/kg; oral; 3 hours) causes hyperalgesia and paw edema, and it reverses carrageenan-induced hyperalgesia in a dose-dependent manner [1]. Tumor growth can be inhibited in vivo by indomethacin sodium (10 mg/mL); oral; once daily for 29 days; male C57BL/6J mice) [2].
|
Cell Assay |
Cell Viability Assay[2]
Cell Types: 3LL-D122 cells (highly metastatic variant of mouse LL cancer cells) Tested Concentrations: 0, 20, 50, 100 and 150μM Incubation Duration: 24 hrs (hours) Experimental Results: Cell viability was inhibited at 20 mM , the inhibition rate reaches 50% at 60 nM. Cell cycle analysis[2] Cell Types: 3LL-D122 cells (highly metastatic variant of mouse LL cancer cells) Tested Concentrations: 0, 30 and 80μM Incubation Duration: 24 hrs (hours) Experimental Results: diminished percentage of cells in G2/M phase and increased in G1 phase Percentage of cells. |
Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat[1]
Doses: 0.01-10 mg/kg Route of Administration: po (po (oral gavage)) 3 hrs (hrs (hours)) Experimental Results: Inhibited carrageenan-induced rat paw edema in a dose-dependent manner (ED50=2.0 mg/kg) and hyperalgesia (ED50=1.5mg/kg). Animal/Disease Models: Male C57BL/6J mice [2] Doses: 10 mg/mL Route of Administration: po (po (oral gavage)) one time/day for 29 days Experimental Results: Delayed the onset of tumor growth and the initial growth rate of footpad tumors. |
References |
[1]. Riendeau D, et, al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.
[2]. Amici C, et, al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell Microbiol. 2015 Sep;17(9):1391-404. [3]. Eli Y, et, al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001 Mar 1;61(5):565-71. |
Molecular Formula |
C19H15NO4CL-.NA+
|
---|---|
Molecular Weight |
379.7695
|
CAS # |
7681-54-1
|
Related CAS # |
Indomethacin;53-86-1;Indomethacin sodium hydrate;74252-25-8
|
SMILES |
O=C([O-])CC1=C(C)N(C(C2=CC=C(Cl)C=C2)=O)C3=C1C=C(OC)C=C3.[Na+]
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6332 mL | 13.1659 mL | 26.3317 mL | |
5 mM | 0.5266 mL | 2.6332 mL | 5.2663 mL | |
10 mM | 0.2633 mL | 1.3166 mL | 2.6332 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.